Cardiovascular risk factors and metabolic syndrome associated with subclinical renal failure;Factores de riesgo cardiovascular y síndrome metabólico asociados a la disfunción renal subclínica: Subanálisis del Registro MESYAS

Medicina Clinica

Volumn 125, Issue 17, 2005, Pages 653-658

  Cordero, Alberto ^a   Laclaustra, Martín ^b   León, Montse ^b   Casasnovas, José A ^b   Grima, Alberto ^c   Nájar, Mónica ^d   Luengo, Emilio ^e   Del Río, Alfonso ^b   Ferreira, Ignacio ^b   Alegría, Eduardo ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c Departamento de Cardiología Preventiva   (Spain)

^d Área de Salud   (Spain)

^e Hospital Militar   (Spain)

Author keywords

Cardiovascular; Metabolic syndrome; Renal dysfunction; Risk factors

Indexed keywords

HIGH DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; SPAIN;

EID: 29144465046     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13081374     Document Type: Article

References (37)

1. National Kidney Foundation. Kidney Disease Outcome Quality Initiative (K/DOQI) clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S76-S110.
2. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999;10:1606-15.
3. Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA. 1998;279:585-92.
4. Henry RMA, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn study. Kidney Int. 2002; 62:1402-7.
5. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the Adult US Population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12.
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305.
7. Mann JF, Gerstein HG, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629-36.
8. Masoudi FA, Plomondon ME, Magid DJ, Sales A, Rumsfeld JS. Renal insuffienciency and mortality from acute coronary syndromes. Am Heart J. 2004;147:623-9.
9. Anavekar NS, McMurray JJ, Velázquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-95.
10. Kearney MT, Fox KA, Lee AJ, Prescott RJ, Shah AM, Batin PD, et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol. 2002;40:1801-8.
11. Chae Cu, Albert CM, Glynn RJ, Guralnik JM, Curhan GC. Mild renal insufficiency and risk of congestive heart failure in men and women ≥ 70 years of age. Am J Cardiol. 2003;92:682-6.
12. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-7.
13. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
14. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Adult Treatment Panel III final report. Circulation. 2002;106:3143-421.
15. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-9.
16. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: a 8-year follow-up of 14,719 initially healthy American women. Circulation. 2003;107:391-7.
17. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in U.S adults. Ann Intern Med. 2004;140:167-74.
18. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens. 2003;16:952-8.
19. Amenábar JJ, García-López F, Robles NR, Saracho R, Pinilla J, Gentil MA, et al. Informe de diálisis y trasplante de la Sociedad Española de Nefrología y Registros autonómicos, año. 2000. Nefrología. 2002;4:310-17.
20. Fernández-Fresnedo G, De Francisco AL, Rodrigo E, Pińera C, Herráez I, Ruiz JC, et al. Insuficiencia renal oculta por valoración de la función renal mediante lacreatinina sérica. Nefrología. 2002;2:144-51.
21. Fernândez-Fresnedo G, De Francisco AL, Rodrigo E, Pinera C, Herrâez I, Ruiz JC, et al. Valoracion del filtrado glomerular mediante la formula peso/creatinina. Med Clin (Barc). 2003;120:485-8.
22. Grima A, Alegría E, Jover P. Prevalencia de los factures de riesgo clásicos en una poblacion laboral mediterránea de 4.996 varones. Rev Esp Cardiol. 1999;52:910-8.
23. Alegria E, Cordero A, Grima A, Casasnovas JA, Laclaustra M, Luengo E, et al. Prevalencia de sindrome metabólico en población laboral española: Registro MESYAS. Rev Esp Cardiol. 2005;58:797-806.
24. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes. 2004;53:1195-200.
25. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
26. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39;S1-S266.
27. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56:2214-9.
28. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125-34.
29. Pérez A. Patologica cardiaca en el paciente con nefropatía crónica. Rev Esp Cardiol. 1998;51:479-86.
30. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of it's parts? Circulation. 2003;108:1546-51.
31. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.
32. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9.
33. Hillege HL, Van Gilst WH, Van Veldhuisen DJ, Navis G, Grobee DE, De Graeff PA, et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibitor: the CATS randomized trial. Eur Heart J. 2003;24:412-20.
34. Tokmakova MP, Skali H, Kenchiah S, Braunwald E, Rouleau JL, Packer M, et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction. The Survival And Ventricular Enlargement (SAVE) study. Circulation. 2004;110:3667-73.
35. Chobanian AV, Bakris GR, Black HF, Cushman WC, Green LA, Izzo JI, et al, for the National Heart, Lung and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-72.
36. González-Juanatey JR, Mazón P, Soria F, Barrios V, Rodríguez L, Bertomeu V. Actualización (2003) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en hipertensión arterial. Rev Esp Cardiol. 2003;56:487-97.
37. Grundy SM, Hansen B, Smith SC, Cleeman JI, Kahn RA, for conference participants. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109:551-6.